Hepatobiliary Cancers: Pathobiology and Translational Advances | EK29

Mar 22, 2021 ‐ Mar 24, 2021



Sessions

Coffee Break iconCoffee Break

Preview Available

Coffee Break

Mar 23, 2021 6:30pm ‐ Mar 23, 2021 6:40pm


Genomic and Epigenomic Studies of Cholangiocarcinoma and their Clinical Implications

Mar 23, 2021 6:40pm ‐ Mar 23, 2021 7:10pm

Speaker(s):

Immune Therapies for HCC: is NASH-HCC Responding Different

Mar 23, 2021 7:10pm ‐ Mar 23, 2021 7:40pm

Speaker(s):

Short Talk: Heterogeneous Liver Cancer Development Promoted by PTEN Regulated beta-Catenin and SOX9 Signal

Mar 23, 2021 7:40pm ‐ Mar 23, 2021 7:55pm

Speaker(s):

Short Talk: Gender Distinct in Genomic Features of HBV-Related Hepatocellular Carcinoma

Mar 23, 2021 7:55pm ‐ Mar 23, 2021 8:10pm

Speaker(s):
  • Chungui Xu, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital

Immunotherapies for Hepatobiliary Cancers: Current Status and Future Perspectives

Mar 24, 2021 10:00am ‐ Mar 24, 2021 10:30am

Speaker(s):

Advances in Molecular and Immune Targeting of Hepatobiliary Cancers

Mar 24, 2021 10:00am ‐ Mar 24, 2021 1:05pm

Co-Chair(s):

Developing Clinical Trials of Novel Therapeutic Agents and Treatment Combinations for Intrahepatic Cholangiocarcinoma

Mar 24, 2021 10:30am ‐ Mar 24, 2021 11:00am

Speaker(s):

Targeted Agent and Immune-Based Therapies for Hepatocellular Carcinoma

Mar 24, 2021 11:00am ‐ Mar 24, 2021 11:30am

Speaker(s):

Coffee Break iconCoffee Break

Preview Available

Coffee Break

Mar 24, 2021 11:30am ‐ Mar 24, 2021 11:40am